Praxis Precision Medicines (PRAX) Stock Price, News & Analysis

Company Overview

Praxis Precision Medicines, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapies for central nervous system disorders characterized by neuronal excitation-inhibition imbalance. It is developing ulixacaltamide, a small molecule inhibitor of T-type calcium channels that is in Phase III clinical trial for the treatment of essential tremor; PRAX-562 for the treatment of pediatric patients with developmental and epileptic encephalopathies (DEE); and PRAX-628 to treat focal epilepsy. The company also develops PRAX-222 for the treatment of pediatric patients with early-onset SCN2A-DEE; PRAX-020 to treat KCNT1 related epilepsies; PRAX-080 for the treatment of PCDH19; and PRAX-090 and PRAX-100 for SYNGAP1 and SCN2A-LoF. It has a license agreement with RogCon Inc.; a research collaboration and license agreement with Ionis Pharmaceuticals, Inc.; a strategic collaboration and license agreement with UCB Biopharma SRL; and collaboration with The Florey Institute to develop three novel ASOs. The company was incorporated in 2015 and is based in Boston, Massachusetts.

Key Stats

• Today's Range: $37.26 to $38.61
• 50-Day Range: $33.55 to $90.77
• 52-Week Range: $30.01 to $91.83
• Volume: 240,733 shs
• Average Volume: 493,933 shs
• Market Capitalization: $771.84 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $123.80
• Consensus Rating: Moderate Buy

Praxis Precision Medicines Stock Analysis - MarketRank™

Praxis Precision Medicines scored higher than 58% of companies evaluated by MarketBeat, and ranked 480th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.4 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Praxis Precision Medicines has received a consensus rating of Moderate Buy. The company's average rating score is 2.80, and is based on 9 buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Praxis Precision Medicines has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Praxis Precision Medicines are expected to decrease in the coming year, from ($10.22) to ($12.22) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Praxis Precision Medicines is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Praxis Precision Medicines is -3.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Praxis Precision Medicines has a P/B Ratio of 4.83. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

9.71% of the float of Praxis Precision Medicines has been sold short.

Short Interest Ratio / Days to Cover

Praxis Precision Medicines has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Praxis Precision Medicines has recently decreased by 31.84%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Praxis Precision Medicines does not currently pay a dividend.

Dividend Growth

Praxis Precision Medicines does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

9.71% of the float of Praxis Precision Medicines has been sold short.

Short Interest Ratio / Days to Cover

Praxis Precision Medicines has a short interest ratio ("days to cover") of 4.

Change versus previous month

Short interest in Praxis Precision Medicines has recently decreased by 31.84%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 1.8 / 5
• News Sentiment: 0.29

News Sentiment

Praxis Precision Medicines has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Praxis Precision Medicines this week, compared to 5 articles on an average week.

Search Interest

9 people have searched for PRAX on MarketBeat in the last 30 days. This is an increase of 80% compared to the previous 30 days.

MarketBeat Follows

Only 3 people have added Praxis Precision Medicines to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Praxis Precision Medicines insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 2.70% of the stock of Praxis Precision Medicines is held by insiders.

Percentage Held by Institutions

67.84% of the stock of Praxis Precision Medicines is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

PRAX Stock Analysis - Frequently Asked Questions

How have PRAX shares performed this year?

Praxis Precision Medicines' stock was trading at $76.96 at the beginning of the year. Since then, PRAX stock has decreased by 50.3% and is now trading at $38.28.
View the best growth stocks for 2025 here.

How were Praxis Precision Medicines' earnings last quarter?

Praxis Precision Medicines, Inc. (NASDAQ:PRAX) announced its earnings results on Friday, February, 28th. The company reported ($2.94) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.76) by $0.18. The business earned $7.48 million during the quarter, compared to the consensus estimate of $0.36 million. Praxis Precision Medicines had a negative net margin of 9,409.22% and a negative trailing twelve-month return on equity of 54.86%.

When did Praxis Precision Medicines' stock split?

Praxis Precision Medicines shares reverse split before market open on Wednesday, November 29th 2023. The 1-15 reverse split was announced on Wednesday, November 29th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, November 29th 2023. An investor that had 100 shares of stock prior to the reverse split would have 7 shares after the split.

When did Praxis Precision Medicines IPO?

Praxis Precision Medicines (PRAX) raised $126 million in an initial public offering on Friday, October 16th 2020. The company issued 7,400,000 shares at a price of $16.00-$18.00 per share. Cowen, Evercore ISI, Piper Sandler and Wedbush PacGrow served as the underwriters for the IPO and Blackstone Capital Markets was co-manager.

Who are Praxis Precision Medicines' major shareholders?

Praxis Precision Medicines' top institutional investors include Price T Rowe Associates Inc. MD (6.48%), Vanguard Group Inc. (5.71%), Capital Research Global Investors (5.33%) and VR Adviser LLC (5.31%). Insiders that own company stock include Alex Nemiroff, Lauren Mastrocola, Dean J Mitchell, Marcio Souza, Timothy Edwin Kelly and Jill Desimone.
View institutional ownership trends.

How do I buy shares of Praxis Precision Medicines?

Shares of PRAX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Praxis Precision Medicines own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Praxis Precision Medicines investors own include NVIDIA (NVDA), Broadcom (AVGO), Meta Platforms (META), Advanced Micro Devices (AMD), Adobe (ADBE), Arista Networks (ANET) and ServiceNow (NOW).

Company Calendar

• Last Earnings: 2/28/2025
• Today: 3/14/2025
• Next Earnings (Estimated): 5/12/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:PRAX
• CIK: 1689548
• Web: www.praxismedicines.com
• Phone: 617-300-8460
• Fax: N/A
• Employees: 110
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $123.80
• High Stock Price Target: $270.00
• Low Stock Price Target: $48.00
• Potential Upside/Downside: +223.4%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.80
• Research Coverage: 10 Analysts

Profitability

• EPS (Most Recent Fiscal Year): ($10.27)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-123,280,000.00
• Net Margins: -9,409.22%
• Pretax Margin: -9,409.22%
• Return on Equity: -54.86%
• Return on Assets: -50.52%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 10.96
• Quick Ratio: 10.96

Sales & Book Value

• Annual Sales: $8.55 million
• Price / Sales: 90.24
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $7.92 per share
• Price / Book: 4.83

Miscellaneous

• Outstanding Shares: 20,163,000
• Free Float: 18,135,000
• Market Cap: $771.84 million
• Optionable: Optionable
• Beta: 2.76